Esperion Therapeutics, Inc. (ESPR) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $3.15 (+0.16%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Sep 25, 2025 | Kristen Kluska | Cantor Fitzgerald | $9.00 | +185.3% |
| Dec 17, 2024 | Kristen Kluska | Cantor Fitzgerald | $8.00 | +153.6% |
| May 4, 2022 | Serge Belanger | Needham | $12.00 | +280.3% |
| May 4, 2021 | Derek Archila | Wells Fargo | $20.00 | +533.9% |
Top Analysts Covering ESPR
ESPR vs Sector & Market
| Metric | ESPR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.24 | 2.40 |
| Analyst Count | 4 | 8 | 19 |
| Target Upside | +1.1% | +11475.0% | +17.1% |
| P/E Ratio | -19.93 | 3.93 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $90M | $95M | $99M | 4 |
| 2026-09-30 | $90M | $101M | $110M | 2 |
| 2026-12-31 | $103M | $116M | $126M | 3 |
| 2027-03-31 | $102M | $114M | $125M | 3 |
| 2027-06-30 | $111M | $125M | $136M | 2 |
| 2027-09-30 | $118M | $133M | $145M | 2 |
| 2027-12-31 | $124M | $140M | $152M | 3 |
| 2028-12-31 | $546M | $553M | $560M | 4 |
| 2029-12-31 | $719M | $885M | $1.03B | 3 |
| 2030-12-31 | $912M | $1.12B | $1.31B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.00 | $0.00 | $0.00 | 3 |
| 2026-09-30 | $0.00 | $0.00 | $0.00 | 1 |
| 2026-12-31 | $0.02 | $0.02 | $0.02 | 1 |
| 2027-03-31 | $0.05 | $0.06 | $0.06 | 1 |
| 2027-06-30 | $0.07 | $0.08 | $0.09 | 1 |
| 2027-09-30 | $0.07 | $0.09 | $0.09 | 1 |
| 2027-12-31 | $0.09 | $0.10 | $0.11 | 1 |
| 2028-12-31 | $-0.53 | $0.34 | $0.99 | 4 |
| 2029-12-31 | $0.89 | $1.17 | $1.42 | 2 |
| 2030-12-31 | $1.26 | $1.67 | $2.03 | 2 |
Frequently Asked Questions
What is the analyst consensus for ESPR?
The consensus among 4 analysts covering Esperion Therapeutics, Inc. (ESPR) is Buy with an average price target of $3.19.
What is the highest price target for ESPR?
The highest price target for ESPR is $20.00, set by Derek Archila at Wells Fargo on 2021-05-04.
What is the lowest price target for ESPR?
The lowest price target for ESPR is $8.00, set by Kristen Kluska at Cantor Fitzgerald on 2024-12-17.
How many analysts cover ESPR?
4 analysts have issued ratings for Esperion Therapeutics, Inc. in the past 12 months.
Is ESPR a buy or sell right now?
Based on 4 analyst ratings, ESPR has a consensus rating of Buy (2.50/5) with a +1.1% upside to the consensus target of $3.19.
What are the earnings estimates for ESPR?
Analysts estimate ESPR will report EPS of $0.00 for the period ending 2026-06-30, with revenue estimated at $95M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.